mavacamten (Camzyos)

From Aaushi
Jump to navigation Jump to search

Indications

* effective in Chinese population[4]

Contraindications

Dosage

Capsules: 2.5 mg, 5 mg, 10 mg, & 15 mg

* echocardiogram for LV ejection fraction prior to initiation

Pharmacokinetics

Drug interactions

Mechanism of action

More general terms

References

  1. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020 Aug 29; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32871100 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext
    Papadakis M, Basu J, Sharma S. Mavacamten: Treatment aspirations in hypertrophic cardiomyopathy. Lancet 2020 Aug 29; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32871101 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31793-1/fulltext
  2. 2.0 2.1 2.2 Wheeler MT, Olivotto I, Elliott PM et al Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption. A Secondary Analysis of the EXPLORER-HCM Randomized Trial. JAMA Cardiol. 2023;8(3):240-247 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36652223 PMCID: PMC9857843 Free PMC article https://jamanetwork.com/journals/jamacardiology/fullarticle/2800305
  3. 3.0 3.1 Desai MY, Owens A, Wolski K et al Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction. Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA Cardiol. Published online August 28, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37639243 https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050
  4. 4.0 4.1 Tian Z, Li L, Li X et al Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. The EXPLORER-CN Randomized Clinical Trial. JAMA Cardiol. Published online August 28, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37639259 https://jamanetwork.com/journals/jamacardiology/fullarticle/2809051
  5. 5.0 5.1 Lou N Mavacamten Shows Promise in Heart Failure With Normal to Supranormal EF. Cardiac myosin inhibitor linked to improvements in biomarkers in small study. MedPage Today September 30, 2024 https://www.medpagetoday.com/meetingcoverage/hfsa/112194
  6. HIGHLIGHTS OF PRESCRIBING INFORMATION CAMZYOS<TM> mavacamten) capsules for oral use https://packageinserts.bms.com/pi/pi_camzyos.pdf

Database